Dynamic Contrast-Enhanced (DCE)-MRI with Gadobutrol for Monitoring Sorafenib Effect on Experimental Prostate Carcinomas

C. C. Cyran1, P. M. Paprottka1, B. Schwarz2, J. von Einem1, S. Sourbron1, O. Dietrich3, R. Hinkel3, C. J. Bruns2, H. Pietsch4, B. J. Wintersperger4, M. F. Reiser1, and K. Nikolaou1

1Institute of Clinical Radiology, Munich University Hospitals - Campus Grosshadern, Munich, Germany, 2Department of Surgery, Munich University Hospitals - Campus Grosshadern, Munich, Germany, 3Department of Cardiology, Munich University Hospitals - Campus Grosshadern, Munich, Germany, 4Contrast Media Research, Bayer Schering Pharma AG, Berlin, Germany

Purpose: To investigate and quantify the anti-angiogenic effect of the multikinase inhibitor Sorafenib on experimental prostate carcinomas in rats with Gadobutrol-enhanced DCE-MRI assays of endothelial permeability and tumor perfusion.

Methods and Materials: A total of 20 Copenhagen rats implanted with subcutaneous prostate carcinoma allografts (MLLB-2) were imaged at baseline and after one-week by dynamic MRI at 3T following enhancement with the small molecular contrast agent Gadobutrol (Gadovist®, Bayer Schering AG, Berlin, Germany). The treatment group (n=10) received daily applications of Sorafenib (10mg/kg bodyweight) via gavage; the control group (n=10) was treated with volume equivalent applications of the solvent of Sorafenib, Cremophor/Ethanol. Quantitative MRI estimates of tumor microvessel permeability (endothelial transfer constant KPS, ml/100ml/min) and tumor plasma flow (tumor perfusion PF; ml/100ml/min) were calculated using the PMI 0.4 software based on a two-compartment kinetic model (1).

Results: Sorafenib significantly suppressed tumor perfusion in prostate carcinoma allografts over the treatment course of one week (PF baseline 47,934 ± 36,855 to Day 7 24,374 ± 18,494 ml/100ml/min). No significant effect was observed on tumor endothelial permeability in the Sorafenib-treated therapy group from baseline to day 7 (KPSbaseline=6.09 ± 4.06 vs. KPSDay7 4.72 ± 2.45 ml/100ml/min, p>0.05), as assayed by Gadobutrol-enhanced MRI. In the control group (n=10) treated daily with volume equivalent applications of the solvent of Sorafenib, Cremophor/Ethanol, tumor perfusion increased significantly over the course of one week (PF baseline 37,635 ± 12,327 vs. Day 7 49,847 ± 14,981 ml/100ml/min, p<0.05). No significant alteration of endothelial permeability was observed in the control group.

Conclusion: Tumor perfusion (ml/100ml/min), as assayed by Gadobutrol-enhanced DCE-MRI can be considered a promising non-invasive surrogate parameter for monitoring anti-angiogenic effects of Sorafenib on an individual tumor basis. As indicated by previous studies (2), small molecular contrast media does not seem to be applicable for non-invasive and reproducible measurements of tumor endothelial permeability by DCE-MRI.

Figure 1. Therapy group perfusion maps depict the significant decrease of tumor perfusion (ml/100ml/min) in subcutaneous prostate carcinomas (white arrows) from baseline to day 7 following a one-week, daily treatment course of Sorafenib (10mg/kg) via gavage.

References: